The pharmaceutical industry is undergoing a profound transformation driven by advancements in Information Technology (IT), with Enterprise Resource Planning (ERP) systems playing a pivotal role in reshaping operations. These systems offer integrated solutions that streamline key business processes, such as production, inventory management, supply chain optimization, regulatory compliance, and data integration, contributing significantly to operational efficiency and organizational agility. This paper explores the evolution and impact of ERP systems within the pharmaceutical sector, highlighting their contributions to overcoming the industry’s inherent challenges, including complex regulatory requirements, the need for accurate and real-time data, and the demand for supply chain resilience. The integration of cloud-based ERP solutions, the incorporation of emerging technologies like Artificial Intelligence (AI), Machine Learning (ML), and the Internet of Things (IoT), and enhanced data analytics capabilities have revolutionized pharmaceutical IT. These advancements not only reduce operational costs, improve forecasting accuracy, and enhance collaboration but also ensure compliance with stringent global regulations, such as Good Manufacturing Practices (GMP) and FDA guidelines. Moreover, ERP systems have been instrumental in managing the pharmaceutical supply chain, ensuring product traceability, and improving inventory control and order fulfillment processes. This manuscript examines how ERP systems enable pharmaceutical companies to maintain high standards of product quality, improve decision-making, and ensure the safety and efficacy of drugs through robust tracking and auditing mechanisms. A case study of a pharmaceutical company that implemented an ERP system demonstrates the tangible benefits, including increased operational efficiency, improved compliance rates, and enhanced customer satisfaction. However, despite the clear advantages, challenges such as customization complexities, data integration issues, and resistance to change remain. As the pharmaceutical industry continues to evolve, ERP systems will remain a cornerstone of digital transformation, facilitating smarter decision-making, better resource management, and enhanced collaboration across global operations. This paper also identifies future trends, including the potential of AI and blockchain technologies in further strengthening ERP systems and transforming the pharmaceutical landscape.

The pharmaceutical supply chain has become increasingly complex and vulnerable to various risks, including counterfeit drugs, diversion, and fraud. As these challenges threaten patient safety and the integrity of global healthcare systems, serialization has emerged as a pivotal innovation in pharmaceutical logistics and regulatory compliance. Serialization involves assigning unique identifiers to individual drug packages, enabling precise tracking and authentication at every stage of the supply chain. This process provides unprecedented transparency, enhances product security, and facilitates real-time monitoring of pharmaceutical products as they move from manufacturers to end consumers. Despite its potential to revolutionize pharmaceutical traceability, the integration of serialization technologies faces numerous obstacles. These include high implementation costs, regulatory inconsistencies across regions, and the technological challenges of managing vast amounts of data. Moreover, the complex, multi-tiered nature of the global supply chain introduces additional risks related to data integrity, cybersecurity, and interoperability between systems. As pharmaceutical companies seek to navigate these challenges, innovations in serialization technology—such as blockchain, artificial intelligence (AI), the Internet of Things (IoT), and radio frequency identification (RFID)—are providing promising solutions to enhance efficiency, reduce fraud, and increase visibility. This manuscript explores both the innovative advancements and the key challenges associated with the integration of serialization in the pharmaceutical supply chain. It delves into the evolving regulatory landscape, highlighting the need for global harmonization of serialization standards, and examines the impact of serialization on securing pharmaceutical distribution networks. Additionally, the paper emphasizes the importance of collaboration among manufacturers, technology providers, and regulatory bodies in overcoming implementation barriers and realizing the full potential of serialization. As the pharmaceutical industry moves towards a more interconnected and data-driven future, serialization promises to play a central role in shaping the next generation of drug safety and supply chain management. By addressing the hurdles to adoption and leveraging emerging technologies, the pharmaceutical sector can create a more secure, transparent, and efficient supply chain that better serves public health and fosters greater trust among consumers and healthcare professionals alike.

Consumer behavior is evolving, demanding a wide range of products with fast shipping and reliable service. The automotive aftermarket industry, worth billions, requires efficient distribution systems to stay competitive. Manufacturers strive to balance growth with product and service excellence. Distributors and retailers face the challenge of maintaining competitive pricing while keeping inventory levels low. An adequate supply chain and accurate product data are crucial for product availability and reducing stock issues. This ultimately increases profits and customer satisfaction.

Failure prediction can be achieved through prognostics, which provides timely warnings before failure. Failure prediction is crucial in an effective prognostic system, allowing preventive maintenance actions to avoid downtime. The prognostics problem involves estimating the remaining useful life (RUL) of a system or component at any given time. The RUL is defined as the time from the current time to the time of failure. The goal is to make accurate predictions close to the failure time to provide early warnings. J S Grewal and J. Grewal provide a comprehensive definition of RUL in their paper "The Kalman Filter approach to RUL estimation." A process is a quadruple (XU f P), where X is the state space, U is the control space, P is the set of possible paths, and f represents the transition between states. The process involves applying control values to change the system's state over time.

Among the most significant systems that organizations of all stripes, whether public or private, use is the Enterprise Resource Planning (ERP) system. Due in large part to the rapid growth of Internet services and the growing reliance on the infrastructure of Cloud service providers, ERP design has advanced, and numerous types of Internet-service-dependent ERP systems have emerged. In addition to the traditional ERP system, the most significant ERP types are Web-based ERP and Cloud ERP. As a result, ERP system vendors and designers, including Oracle and SAP, are relying on cloud-based ERP system design, and offering the ERP system as a service for monthly and annual subscription, where the system is external to the organization and does not need to exist within the organization.

The digital drug traceability systems ensure the patient-centric dose, dosage form, and strength delivered to the patient as intended in the supply chain. It helps the digital healthcare platforms securely establish drug information supplied to patients for potential treatments. Therefore, it is important for the global supply chain to explore the number of high-end digital health solutions and drug traceability to create an interactive loop on drug security for patients. This article provides an overview of advanced technologies for digital drug traceability, such as blockchain, that would establish a secure pharmaceutical supply chain for the digital world.

Our lives are becoming more and more digital, and this has an impact on how we work, study, communicate, and interact. Businesses are currently digitally altering their information systems, procedures, culture, and strategy. Existing businesses and economies are severely disrupted by the digital revolution. The Internet of Things, microservices, and mobile services are examples of IT systems with numerous, dispersed, and very small structures that are made possible by digitization. Utilizing the possibilities of cloud computing, mobile systems, big data and analytics, services computing, Internet of Things, collaborative networks, and decision support, numerous new business prospects have emerged throughout the years. The logical basis for robust and self-optimizing run-time environments for intelligent business services and adaptable distributed information systems with service-oriented enterprise architectures comes from biological metaphors of living, dynamic ecosystems. This has a significant effect on how digital services and products are designed from a value- and service-oriented perspective. The evolution of enterprise architectures and the shift from a closed-world modeling environment to a more flexible open-world composition establish the dynamic framework for highly distributed and adaptive systems, which are crucial for enabling the digital transformation. This study examines how enterprise architecture has changed over time, taking into account newly established, value-based relationships between digital business models, digital strategies, and enhanced enterprise architecture.

Both crucial success and critical failure factors are included in the current review work. The method relies on creating surveys to collect optional data. It describes the terms that are used to obtain research papers on the ERP deployment in Enterprise Business from databases and scholarly research. In order to enhance the quality of papers, it also includes the consideration and restriction criteria. At that time, a thorough audit of the available papers is conducted to determine the impact of ERP use in Enterprise Business. Important elements are found that determine whether ERP deployments are successful or unsuccessful, as well as how they actually affect Enterprise Business (insert actual success and failure variables here aside from impact). The time span during which research publications have been evaluated limits the scope of the study presented in this paper. One implicit drawback is that it only considers the state of the art in the field of study, without taking into account an empirical investigation. Nevertheless, its findings may prove advantageous, and the directions for future research aid in expanding the field of study. This work advances the body of knowledge regarding the potential benefits and drawbacks of ERP adoption for small and medium-sized enterprises. It uses a secondary data collection strategy to identify important success factors, important failure factors, and their impact. The insights will assist Enterprise Business, Enterprise Business' stakeholders, and ERP service providers in understanding the causes of success or failure and in taking the appropriate action.